Communiqués Definium Therapeutics, Inc. Deutsche Boerse AG

Actions

MMQ0

CA24477V1058

Recherche biotechnologique et médicale

Marché Fermé - Deutsche Boerse AG 15:01:53 08/10/2026			Après clôture 22:00:31
30,40 ^EUR	-4,40%		30,60	+0,66%

30/09	Un initié de Definium Therapeutics a vendu des actions pour 1 153 784 dollars, selon un récent document déposé auprès de la SEC	MT
14/09	Les experts pressent la FDA d'établir des normes claires de sécurité et d'accès pour les psychédéliques (14 septembre)	RE

Communiqués

28/09	Definium Therapeutics Announces New Employee Inducement Grants	BU
14/09	Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder	BU
14/09	Definium Therapeutics Announces New Employee Inducement Grants	BU
13/09	Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026	BU
10/09	Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026	BU
08/09	Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results	BU
31/08	Definium Therapeutics Announces New Employee Inducement Grants	BU
26/08	Definium Therapeutics to Participate at Upcoming Investor Conferences and Events	BU
17/08	Definium Therapeutics Announces New Employee Inducement Grants	BU
12/08	Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder	BU
07/08	Definium Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights	BU
03/08	Definium Therapeutics Announces New Employee Inducement Grants	BU
30/07	Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026	BU
20/07	Definium Therapeutics Announces New Employee Inducement Grants	BU
16/07	Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology	BU
14/07	New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)	BU
06/07	Definium Therapeutics Announces New Employee Inducement Grants	BU
25/06	Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares	BU
24/06	Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering	BU
22/06	Definium Therapeutics, Inc. Announces Proposed Public Offering	BU
22/06	Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder	BU
21/06	Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026	BU
15/06	Definium Therapeutics Announces New Employee Inducement Grants	BU
01/06	Definium Therapeutics Announces New Employee Inducement Grants	BU